GNIPST Bulletin 22.2

7/29/2019 GNIPST Bulletin 22.2

1/14

1118-1177-4796-9849-7562-5062 mail

GNIPST BULLETIN 2012

25 th January 2013 Volume No.: 22 Issue No.: 02

Contents Message from GNIPST

Letter to the Editor News Update Disease Outbreak News Health Awareness Forth Coming Events Drugs Update Campus News Students Section Editors Note Archive

Vision

TO GROW AS A CENTRE OF EXCELLENCE IN THE FIELD OF

PHARMACEUTICAL AND BIOLOGICAL SCIENCE

EDITOR: Debabrata Ghosh Dastidar

GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE ANDTECHNOLOGY

GNIPST Photo Gallery For your comments/contribution OR

For B ack-Issues , mailto:[email protected]

1
https://picasaweb.google.com/111714720327580099858/Tour2013mailto:[email protected]:[email protected]:[email protected]://picasaweb.google.com/111714720327580099858/Tour2013


2/14

25-01-2013

MESSAGE FROM GNIPST

All the members of GNIPST are proud to publish the 22 nd Volume

of GNIPST BULLETIN. This bulletin has successfully completed

its twenty months journey. We hope it has kept the readers updated

of recent activities in pharmaceutical & biological sciences and also

introduced them with the different activities of our esteemed

institution. We are thankful to all of you for your great cooperation

& support and are looking forward to the samein future.

LETTER TO THE EDITOR .

NEWS UPDATE

'Quadruple Helix' DNA Discovered in Human Cells(20 JANUARY 2013 )

In 1953, Cambridge researchers Watson and Crick published anarticle describing the interweaving "double helix" DNA structure --

the chemical code for all life. Now, in the year of that scientific

landmark's 60th Anniversary, Cambridge researchers have

published another article demonstrating that four-stranded

"quadruple helix" DNA structures -- known as G-quadruplexes --

also exist within the human genome.

One Form of Neuron Turned Into Another in Brain(20 JANUARY 2013 )

Click here to go at the top 1
http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


3/14

25-01-2013

A new finding by stem cell biologists turns one of the basics of

neurobiology on its head -- demonstrating that it is possible to turn

one type of already differentiated neuron into another within the

brain.

Regular Aspirin Use Linked to Increased Risk ofAge- Related Macular Degeneration(21 JANUARY 2013 )

Regular aspirin use appears to be associated with an increased riskof neovascular age-related macular degeneration, which is a leading

cause of blindness in older people, and it appears to be independent

of a history of cardiovascular disease and smoking.

New Way to Kill Lymphoma Without Chemo-

therapy: Golden Nanoparticle Starves Cancer

Cell to Death (21 JANUARY 2013 )

Scientists annihilated lymphoma by depriving it of a favorite food:

HDL cholesterol. Researchers developed a new golden nanoparticle

that's a replica of natural HDL. Acting like a secret double agent,

the particle appears to the human lymphoma cell like natural HDL.

But when the cell engages it, the particle plugs up the cell and

blocks cholesterol from entering. The cell dies.

http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


4/14

25-01-2013

Immune Cells Engineered in Lab to Resist HIV

In fection, Study Shows (22 JANUARY 2013 )

Researchers have found a novel way to engineer key cells of theimmune system so they remain resistant to infection with HIV, the

virus that causes AIDS. The new approach, a form of tailored gene

therapy, could ultimately replace drug treatment, in which patients

have to take multiple medications daily to keep the virus in check

and prevent the potentially fatal infections wrought by AIDS.

How Can Evolutionary Biology Explain Why We Get

Cancer? (22 JANUARY 2013 )

Over 500 billion cells in our bodies will be replaced daily, yet

natural selection has enabled us to develop defenses against thecellular mutations which could cause cancer. It is this relationship

between evolution and the bodys fight against cancer which is

explored in a new special issue of the Open Access journal

Evolutionary Applications. Low Vitamin D Levels Linked to High Risk of

Premenopausal Breast Cancer (24 JANUARY 2013 )Low serum vitamin D levels in the months preceding diagnosis may

predict a high risk of premenopausal breast cancer.

http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


5/14

25-01-2013

Stem Cell Therapy to Repair Damaged Knee

Cartilage (24 JANUARY 2013 )

Medical researchers are conducting the first clinical study in theU.S. of an innovative stem cell drug, Cartistem, to repair knee

cartilage damaged by aging, trauma or degenerative diseases such as

osteoarthritis.

HEALTH AWARENESS

Measles

Measles is a highly contagious, serious disease caused by a virus. In

1980, before widespread vaccination, measles caused an estimated

2.6 million deaths each year.

It remains one of the leading causes of death among young children

globally, despite the availability of a safe and effective vaccine. An

estimated 157 700 people died from measles in 2011 mostly

children under the age of five.

Measles is caused by a virus in the paramyxovirus family. Themeasles virus normally grows in the cells that line the back of the

throat and lungs. Measles is a human disease and is not known to

occur in animals.

http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29


6/14

25-01-2013

Accelerated immunization activities have had a major impact on

reducing measles deaths. Since 2000, more than one billion children

in high risk countries were vaccinated against the disease through

mass vaccination campaigns about 225 million of them in 2011.

Global measles deaths have decreased by 71% from 548,300 to 157

700.

Signs and symptoms

The first sign of measles is usually a high fever, which begins about10 to 12 days after exposure to the virus, and lasts four to seven days.

A runny nose, a cough, red and watery eyes, and small white spots

inside the cheeks can develop in the initial stage. After several days,

a rash erupts, usually on the face and upper neck. Over about three

days, the rash spreads, eventually reaching the hands and feet. The

rash lasts for five to six days, and then fades. On average, the rash

occurs 14 days after exposure to the virus (within a range of seven

to 18 days).

Severe measles is more likely among poorly nourished young

children, especially those with insufficient vitamin A, or whose

immune systems have been weakened by HIV/AIDS or otherdiseases.

Most measles-related deaths are caused by complications

associated with the disease. Complications are more common in



7/14

25-01-2013

children under the age of five, or adults over the age of 20. The most

serious complications include blindness, encephalitis (an infection

that causes brain swelling), severe diarrhoea and related

dehydration, ear infections, or severe respiratory infections such as

pneumonia. As high as 10% of measles cases result in death among

populations with high levels of malnutrition and a lack of adequate

health care. Women infected while pregnant are also at risk of

severe complications and the pregnancy may end in miscarriage or

preterm delivery. People who recover from measles are immune forthe rest of their lives.

Who is at risk?

Unvaccinated young children are at highest risk of measles and its

complications, including death. Unvaccinated pregnant women are

also at risk. Any non-immune person (who has not been vaccinated or was vaccinated but did not develop immunity) can become

infected.

Measles is still common in many developing countries particularly

in parts of Africa and Asia. More than 20 million people are affected

by measles each year. The overwhelming majority (more than 95%)of measles deaths occur in countries with low per capita incomes

and weak health infrastructures.



8/14

25-01-2013

Measles outbreaks can be particularly deadly in countries

experiencing or recovering from a natural disaster or conflict.

Damage to health infrastructure and health services interrupts

routine immunization, and overcrowding in residential camps

greatly increases the risk of infection.

Transmission

The highly contagious virus is spread by coughing and sneezing,

close personal contact or direct contact with infected nasal orthroat secretions.

The virus remains active and contagious in the air or on infected

surfaces for up to two hours. It can be transmitted by an infected

person from four days prior to the onset of the rash to four days after

the rash erupts.

Measles outbreaks can result in epidemics that cause many deaths,

especially among young, malnourished children. In countries where

measles has been largely eliminated, cases imported from other

countries remain an important source of infection.

Treatment

No specific antiviral treatment exists for measles virus.



9/14

25-01-2013

Severe complications from measles can be avoided though

supportive care that ensures good nutrition, adequate fluid intake

and treatment of dehydration with WHO-recommended oral

rehydration solution. This solution replaces fluids and other

essential elements that are lost through diarrhoea or vomiting.

Antibiotics should be prescribed to treat eye and ear infections, and

pneumonia.

All children in developing countries diagnosed with measles should

receive two doses of vitamin A supplements, given 24 hours apart.

This treatment restores low vitamin A levels during measles that

occur even in well-nourished children and can help prevent eye

damage and blindness. Vitamin A supplements have been shown to

reduce the number of deaths from measles by 50%.

Prevention

Routine measles vaccination for children, combined with mass

immunization campaigns in countries with high case and death

rates, are key public health strategies to reduce global measles

deaths. The measles vaccine has been in use for over 40 years. It is

safe, effective and inexpensive. It costs less than one US dollar toimmunize a child against measles.



10/14

25-01-2013

The measles vaccine is often incorporated with rubella and/or

mumps vaccines in countries where these illnesses are problems. It

is equally effective in the single or combined form.

In 2011, about 84% of the world's children received one dose of

measles vaccine by their first birthday through routine health

services up from 72% in 2000. Two doses of the vaccine are

recommended to ensure immunity and prevent outbreaks, as about

15% of vaccinated children fail to develop immunity from the first

dose.

DISEASE OUTBREAK NEWS

FORTHCOMING EVENTS

1st international conference on emerging trends in chemica

pharmaceutical sciences and First convention of ICCPDate: 28 Jun 2013 30 Jun 2013, Location: Jawaharlal Nehru Technologic

University, Anantapur campus, Anantapur, Andhra Pradesh.

DRUGS UPDATES

FDA approves Exjade to remove excess iron in

patients with genetic blood disorder

(23 JANUARY 2013 )

http://www.publication4u.com/link.php?M=102715&N=9&L=2&F=Hhttp://www.publication4u.com/link.php?M=102715&N=9&L=2&F=Hhttp://www.publication4u.com/link.php?M=102715&N=9&L=2&F=H


11/14

25-01-2013

The U.S. Food and Drug Administration expanded the approved

use of Exjade (deferasirox)to treat patients ages 10 years and older

who have chronic iron overload resulting from a genetic blood

disorder called non-transfusion-dependent thalassemia (NTDT).

CAMPUS NEWS

STUDENTS SECTION

WHO CAN ANS WER FIRS T ???

() Which toxin was also known as sausage

poison?

() Project 523 was established by Chinese army to

discover the new treatment strategy for which

disease?

A) Camptothecin B) Camptotheca acuminata

[email protected]

mailto:[email protected]:[email protected]:[email protected]://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336478.htm


12/14

25-01-2013

EDITORS NOTE

I am very happy to publish the 2 nd issue of 22 nd Volume of GNIPST

BULLETIN. It is my great pleasure to introduce you to the newly

launched facebook account GNIPST bulletin . You are cordially

invited to add this account to your friend list. The current issues will

also be directly available on facebook.

I would like to convey my thanks to all the GNIPST members and

the readers for their valuable comments, encouragement& supports.Special thanks to Dr. Prerona Saha for her advice; Mr. Soumya

Bhattacharya, for his contribution in students section .

It would be my great pleasure to receive the contributions,

suggestions & feedback from your desk for further upliftment of this

deliberation GNIPST BULLETIN.

ARCHIVE

The general body meeting of APTI, Bengal Branch has been

conducted at GNIPST on 15th June, 2012. The programme started

with a nice presentation by Dr. Pulok Kr. Mukherjee, School of

Natural Products, JU on the skill to write a good manuscript for

publication in impact journals. It was followed by nearly two hour

long discussion among more than thirty participants on different



13/14

25-01-2013

aspects of pharmacy education. Five nonmember participants

applied for membership on that very day.

GNIPST is now approved by AICTE and affiliated to WBUT forconducting the two years post graduate course (M.Pharm) in

The approved number of seat is 18.

The number of seats in B.Pharm. has been increased from60 to 120.

2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceut

Molecular Imaging (PET/CT), Targeted Radionuclide Therapy, and Dos(SWC-2013) : On the Way to Personalized Medicine

Dates 28 Feb 2013 02 Mar 2013

Location: Chandigarh, India.

AICTE has sanctioned a release of grant under Research

Promotion Scheme (RPS) during the financial year 2012-

13to GNIPST as per the details below:

a. Beneficiary Institution: Guru Nanak Institution of

Pharmaceutical Science & Technology.

b. Principal Investigator: Dr. LopamudraDutta.

c. Grant-in-aid sanctioned: Rs. 16,25000/- only

d. Approved duration: 3 years

e. Title of the project: Screening and identification of potential

medicinal plant of Purulia&Bankura districts of West Bengal with

http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/


14/14

25-01-2013

respect to diseases such as diabetes, rheumatism, Jaundice,

hypertension and developing biotechnological tools for enhancing

bioactive molecules in these plant.

Special classes on Communication Skills, G.D. and

Interview will commence from 3rd week of January 2013

for the students of this Institute. Interested students are

required to contact the undersigned for enrolment either

personally or by e-mail.

Dr. LopamudraDatta E-mail : [email protected]

[email protected]

mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]

GNIPST Bulletin 22.2

Documents

Transcript of GNIPST Bulletin 22.2